PapersFlow Research Brief
Diagnosis and Treatment of Venous Diseases
Research Guide
What is Diagnosis and Treatment of Venous Diseases?
Diagnosis and Treatment of Venous Diseases encompasses the clinical assessment, classification, and therapeutic interventions for chronic venous disorders, including chronic venous insufficiency, varicose veins, venous ulcers, and venous thromboembolism.
This field addresses management of chronic venous disorders through modalities such as endovenous treatment, compression therapy, and sclerotherapy, with 51,069 papers documenting its scope. The CEAP classification system for chronic venous disorders was revised to improve diagnostic standardization, as detailed in "Revision of the CEAP classification for chronic venous disorders: Consensus statement" (2004). Venous thromboembolism affects approximately 100 persons per 100,000 annually in the United States, rising exponentially with age to 500 cases per 100,000 at age 80, according to "The Epidemiology of Venous Thromboembolism" (2003).
Topic Hierarchy
Research Sub-Topics
Endovenous Thermal Ablation for Varicose Veins
This sub-topic evaluates radiofrequency and laser ablation techniques for treating superficial venous reflux, comparing efficacy, recurrence rates, and complications in randomized trials. Researchers optimize energy delivery protocols and catheter designs.
Compression Therapy in Chronic Venous Insufficiency
Studies assess multilayer bandaging, stockings, and intermittent pneumatic devices for ulcer healing and symptom relief in CEAP-classified CVI patients. Research includes adherence factors and hemodynamic effects.
Sclerotherapy for Telangiectasias and Reticular Veins
This area investigates foam and liquid sclerosants for cosmetic and symptomatic treatment of C1 venous disease, focusing on hyperpigmentation risks and ultrasound guidance. Long-term studies track recurrence.
Management of Venous Leg Ulcers
Researchers trial pentoxifylline, growth factors, and bioengineered skin substitutes alongside compression for C6 ulcers. Systematic reviews synthesize evidence on healing trajectories and prevention.
Epidemiology of Chronic Venous Disorders
Population-based studies estimate CEAP-classified CVD prevalence, risk factors like obesity and parity, and geographic variations using standardized classifications. Projections model future healthcare burden.
Why It Matters
Chronic venous disorders impose a substantial health economic burden, with chronic wounds affecting 6.5 million patients in the United States and costing an excess of US$25 billion annually, as reported in "Human skin wounds: A major and snowballing threat to public health and the economy" (2009). Venous leg ulcers, a key component, challenge healthcare resources globally, with treatments like compression therapy and sclerotherapy targeting pathophysiology outlined in "Challenges in the Treatment of Chronic Wounds" (2015). Oral anticoagulants such as apixaban demonstrated noninferiority to conventional therapy for acute venous thromboembolism with significantly less bleeding in clinical trials, per "Oral Apixaban for the Treatment of Acute Venous Thromboembolism" (2013), reducing recurrence risks. Edoxaban similarly showed noninferiority to warfarin with lower bleeding rates in "Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism" (2013), informing guideline-directed antithrombotic strategies from "Antithrombotic Therapy for Venous Thromboembolic Disease" (2008). The revised CEAP classification by Eklöf et al. (2004) in "Revision of the CEAP classification for chronic venous disorders: Consensus statement" standardizes diagnosis, aiding consistent treatment across vascular surgery practices.
Reading Guide
Where to Start
"Revision of the CEAP classification for chronic venous disorders: Consensus statement" (2004) by Eklöf et al., as it provides the foundational diagnostic framework essential for understanding subsequent treatment papers.
Key Papers Explained
Eklöf et al.'s "Revision of the CEAP classification for chronic venous disorders: Consensus statement" (2004) establishes diagnostic standards that underpin epidemiology in White's "The Epidemiology of Venous Thromboembolism" (2003), which quantifies VTE incidence. Frykberg and Banks' "Challenges in the Treatment of Chronic Wounds" (2015) applies these to wound management, while Agnelli et al.'s "Oral Apixaban for the Treatment of Acute Venous Thromboembolism" (2013) and Büller's "Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism" (2013) build evidence for targeted pharmacotherapy, and Kearon et al.'s "Antithrombotic Therapy for Venous Thromboembolic Disease" (2008) synthesizes guidelines.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Consensus guidelines from Kearon et al. in "Antithrombotic Therapy for Venous Thromboembolic Disease" (2008) guide current antithrombotic choices amid DOAC adoption. Wound care advances target persistent challenges noted by Frykberg and Banks (2015), with no recent preprints shifting focus.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Correspondence - Tranexamic acid for traumatic brain injury | 2005 | Edinburgh Research Exp... | 11.7K | ✓ |
| 2 | Comparison of global estimates of prevalence and risk factors ... | 2013 | The Lancet | 3.3K | ✕ |
| 3 | Human skin wounds: A major and snowballing threat to public he... | 2009 | Wound Repair and Regen... | 2.9K | ✓ |
| 4 | Challenges in the Treatment of Chronic Wounds | 2015 | Advances in Wound Care | 2.4K | ✓ |
| 5 | The Epidemiology of Venous Thromboembolism | 2003 | Circulation | 2.3K | ✕ |
| 6 | Oral Apixaban for the Treatment of Acute Venous Thromboembolism | 2013 | New England Journal of... | 2.2K | ✓ |
| 7 | Antithrombotic Therapy for Venous Thromboembolic Disease | 2008 | CHEST Journal | 2.0K | ✕ |
| 8 | Bypass versus angioplasty in severe ischaemia of the leg (BASI... | 2005 | The Lancet | 1.9K | ✕ |
| 9 | Revision of the CEAP classification for chronic venous disorde... | 2004 | Journal of Vascular Su... | 1.9K | ✓ |
| 10 | Edoxaban versus Warfarin for the Treatment of Symptomatic Veno... | 2013 | New England Journal of... | 1.8K | ✓ |
Frequently Asked Questions
What is the CEAP classification in venous diseases?
The CEAP classification system categorizes chronic venous disorders by clinical signs (C), etiology (E), anatomy (A), and pathophysiology (P). "Revision of the CEAP classification for chronic venous disorders: Consensus statement" (2004) by Eklöf et al. revised it through consensus to enhance diagnostic precision and comparability in research and practice.
How prevalent is venous thromboembolism?
Venous thromboembolism occurs for the first time in approximately 100 persons per 100,000 each year in the United States. Incidence rises exponentially from under 5 cases per 100,000 in those under 15 years to about 500 cases per 100,000 at age 80, as documented in "The Epidemiology of Venous Thromboembolism" (2003) by White.
What treatments are used for acute venous thromboembolism?
Apixaban as a fixed-dose regimen alone proved noninferior to conventional therapy for acute venous thromboembolism with less bleeding, according to "Oral Apixaban for the Treatment of Acute Venous Thromboembolism" (2013) by Agnelli et al. Edoxaban after initial heparin was noninferior to warfarin with reduced bleeding in "Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism" (2013) by Büller.
What is the economic impact of chronic venous ulcers?
Chronic wounds, including venous leg ulcers, affect 6.5 million patients in the United States, with annual treatment costs exceeding US$25 billion. This burden grows due to aging populations and rising diabetes incidence, per "Human skin wounds: A major and snowballing threat to public health and the economy" (2009) by Sen et al.
What challenges exist in treating chronic venous wounds?
Chronic wounds like venous leg ulcers resist healing due to persistent inflammation and biofilm issues, consuming global healthcare resources. "Challenges in the Treatment of Chronic Wounds" (2015) by Frykberg and Banks reviews pathophysiology and multimodal approaches including debridement and advanced dressings.
Open Research Questions
- ? How can diagnostic imaging improve early detection of chronic venous insufficiency progression to ulcers?
- ? What biomarkers predict response to endovenous treatments versus sclerotherapy in varicose veins?
- ? Which antithrombotic regimens minimize bleeding risks in elderly patients with recurrent venous thromboembolism?
- ? How does the revised CEAP classification correlate with quality-of-life outcomes post-treatment?
- ? What factors drive the health economic burden of venous ulcers beyond direct treatment costs?
Recent Trends
The field maintains steady documentation with 51,069 papers, emphasizing established treatments like DOACs over five years without specified growth.
High-citation works from 2003-2015, such as White's VTE epidemiology and Eklöf et al.'s CEAP revision (2004), anchor ongoing clinical practice, with no new preprints or news in the last 12 months.
2003Research Diagnosis and Treatment of Venous Diseases with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Diagnosis and Treatment of Venous Diseases with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers